IOM Proposal Could Open Door For Biomarkers In Supplement Research
This article was originally published in The Tan Sheet
Executive Summary
An Institute of Medicine report recommending a framework for assessing biomarkers for food and supplement health claims could help the supplement industry because it "will set the stage for being able to validate more biomarkers," said Andrew Shao, senior VP of scientific and regulatory affairs with the Council for Responsible Nutrition
You may also be interested in...
FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More
Agency says "some credible evidence" suggests intake of EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.
Omega-3 Petition Outcome Will Reveal FDA Biomarker Stance
A citizen petition for omega-3 cardiovascular health claims is the first since the Institute of Medicine in 2010 recommended a framework to assess biomarkers for supplement health claims. The petition also will show whether FDA changed its thinking about supplement claims, says former FDA dietary supplement programs head Bill Frankos.
Omega-3 Petition Outcome Will Reveal FDA Biomarker Stance
A citizen petition for omega-3 cardiovascular health claims is the first since the Institute of Medicine in 2010 recommended a framework to assess biomarkers for supplement health claims. The petition also will show whether FDA changed its thinking about supplement claims, says former FDA dietary supplement programs head Bill Frankos.